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A Decentralized, Patient-Centered Approach to Diabetes
Disease Management in the Primary Care Setting
MICHAEL TOSCANI, Pharm.D.,1 JOHN P. O’CONNOR, Ph.D.,2
and DAVID B. NASH, M.D., M.B.A.2
ABSTRACT
Although many disease management programs have been developed for diabetes, no single
design has proved best for all providers and patient populations. Cost effectiveness is espe-
cially relevant to diabetes programs because significant costs of the disease may come from
complications that occur later in life, while the costs of the program are incurred immedi-
ately. For this reason, diabetes disease management programs with positive outcomes and
low implementation costs are of particular importance. We report here on the outcomes of a
pilot test of the Steps to Health™ program developed by Abbott Laboratories. The Steps to
Health™ program was designed to improve patients’ compliance for their diabetes care by
increasing their knowledge and understanding of diabetes. The pilot test format utilized a
decentralized approach to implement the Steps to Health™ program and included assess-
ments of clinical, process, and quality-of-life outcomes. The study used a prospective, obser-
vational, pre-post design. Patients were assessed at enrollment and at 6 months. The primary
clinical outcome was glycemic control, as measured by HbA1c. For the 70 patients (18% of en-
rollment) with complete baseline and endpoint data, mean decrease in HbA1c was 1.7% (p ,
0.0001). Clinical process measures of preventive diabetes care showed minor changes in rates
between the pre- and postenrollment periods. There was also significant improvement in pa-
tient satisfaction regarding their knowledge of diabetes, overall ability to take care of dia-
betes, and helpfulness of the information received. These results suggest that a diabetes dis-
ease management program that is relatively inexpensive and easy to implement, centered on
patient education in self-management, can achieve clinically significant improvements in gly-
cemic control for a specific period of time (6 months) and result in a high level of patient sat-
isfaction.
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INTRODUCTION
DIABETES MELLITUS is among the most preva-lent chronic diseases in the United States,
afflicting 5.9% of the population.1 Diabetes and
its complications have a dramatic impact on
health, quality of life, and healthcare expendi-
tures. The economic effects of excess morbid-
ity and lost productivity are significant. As the
U.S. population ages, the disease will afflict in-
creasing numbers of the 10.3 million diagnosed
and the additional 5.4 million undiagnosed
(1998)1 at ages when the toll is most severe.
The American Diabetes Association has re-
1HealthAnswers, Inc., Pennington, New Jersey.
2Office of Health Policy, Thomas Jefferson University, Philadelphia, Pennsylvania.
cently published detailed standards of preven-
tive care for patients with diabetes.2 These
guidelines are evidence-based, including results
of randomized, controlled trials, and are fre-
quently updated. Despite the availability of con-
sensus-based best practices, it is well docu-
mented that the nationwide standard of practice
falls short of these goals.3 This is the result of
many factors, including the insidious nature of
the disease, the time required of healthcare
providers in education and follow-up that
would induce and maintain positive changes in
patient and physician behavior, and the infra-
structure and resources required for proactive,
population-based management of the disease.
One way to address the complexity of man-
aging diabetes in the primary care setting is to
supplement physician efforts through disease
management programs. There is a multiplicity
of such programs for diabetes; no single design
has proven best for all providers and patient
populations. Sponsors of such plans include
payors, employers, and healthcare suppliers
and providers. For all sponsors, a key issue is
the cost effectiveness of disease management
interventions. This is especially relevant to di-
abetes because significant costs of the disease
come from complications that may occur later
in life, while the costs of a disease management
program are incurred immediately. Thus, esti-
mating and comparing the costs and benefits
of disease management is especially difficult in
diabetes, and this has impeded a widespread
acceptance of a variety of different programs.
For this reason, diabetes disease management
programs with noteworthy outcomes and low
implementation costs are of particular impor-
tance.
We report here on the outcomes of a pilot
test of such a program, the Steps to Health™
program developed by Abbott Laboratories.
The Steps to Health™ program focused on im-
proving overall health status, quality of life,
and quality of care. It was designed to improve
patients’ compliance for their diabetes care by
increasing their knowledge and understanding
of diabetes. This would assist in their ability to
make informed choices regarding their care.
The link between lack of glycemic control and
onset of diabetic complications has been docu-
mented.4 For this reason, the program design
is centered primarily on improving HbA1c lev-
els by increasing patient education and fre-
quency of patient self monitoring of glucose
levels. Patient education also encompassed the
ADA-recommended guidelines regarding peri-
odic retinal exams, foot exams, and laboratory
tests of lipid levels, creatinine, and albumin.
The program was based on training patients to
plan their diabetes care using a detailed daily
organizer, the Steps to Health™ Diabetes Plan-
ner. A diabetes educator was used to review
the planner by conducting 1-hour training sem-
inars designed for either one-to-one or group
sessions. In addition, patients were given a
blood glucose meter (Precision Q.I.D.®) with
access to 24-hour phone training and support.
The patients were then sent quarterly reminder
cards regarding periodic physician visits and
health tips. Provider education was made
available with the program, although the pri-
mary focus was on patient education and the
care that patients should be receiving from
their physician. Provider education included
the following three diabetes monographs:
1. See Diabetes through the Patient’s Eyes
2. Type 2 Diabetes: The Silent Epidemic
3. HbA1c: The Key to Glycemic Control
MATERIALS AND METHODS
A pilot study of the program was sponsored
by Abbott Laboratories and Columbia/HCA in
collaboration with physicians in an affiliated
diabetes clinic as well as primary care physi-
cians in practice in the Nashville area. The
sponsors wanted a pilot test format that could
be completed within 2 years and would include
clinical, process, and quality-of-life outcomes.
Patient enrollment required more time than 
anticipated; as a result, patients were followed
for 6 months instead of 1 year as originally
planned.
Economic outcomes were not included in the
evaluation because of the short time frame and
limitations associated with collecting health
services utilization for the patient population
in the study.
The study utilized a decentralized approach
for the implementation of the Steps to Health™
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program. This included a patient-focused
model to emphasize education and to provide
tools for compliance. The decentralized ap-
proach was designed for voluntary participa-
tion by physicians and patients. It did not re-
quire physicians to standardize patient care
regarding therapy guidelines treatments, ap-
pointments, or procedures. The study did not
explicitly attempt to change physician behav-
ior, and their participation consisted simply of
allowing the study coordinator to review charts
of those patients enrolled in the program. The
study used a prospective, observational, pre-
post design. Patients were assessed at enroll-
ment and at 6 months. Analysis of each out-
come was performed on an intent-to-treat
basis, including all enrolled patients for whom
baseline and endpoint data were available.
The primary clinical outcome was glycemic
control, as measured by a change in HbA1c.
Stratified analysis was necessary for character-
ization of change in HbA1c because the en-
rolled population varied significantly with re-
spect to level of control at baseline. Absolute
change in HbA1c and even a percentage re-
duction are harder to achieve for patients with
lower baseline levels and do not have the same
clinical significance as for patients with high
levels. Therefore, patients were stratified into
four groups based on HbA1c at enrollment: 
in control (,7), borderline (7–8), moderate
(8.1–10), and severe (.10). These strata were
analyzed individually.
The following clinical process measures were
also assessed by noting whether tests were per-
formed in the 6-month periods pre- and post-
enrollment: retinal exam, foot exam, HbA1c,
urinalysis, glucose, albumin, creatinine, and
lipids.
Patient health-related quality of life and
satisfaction with the diabetes program were
assessed using the Medical Outcomes Study
12 Item Short Form (SF-12®) and a cus-
tomized satisfaction questionnaire adminis-
tered at enrollment and at 6 months. Provider
satisfaction was also assessed in a customized
questionnaire administered at the end of the
study.
Data collection was done by patient survey
and chart abstraction. Charts were reviewed in-
dividually, and the data for the 12-month study
period were entered onto a case report form.
These data were then entered in a database for
statistical analysis using SAS (version 6.12). Be-
cause the program was not coordinated with
the physicians’ scheduling of individual pa-
tients, a range of 6 months plus or minus 1
month was used in interpreting the pre- and
postenrollment data. Patients were enrolled on
a rolling basis, beginning in January 1998, with
the final patient completing the pilot study in
September 1999.
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TABLE 1. PATIENT DEMOGRAPHICS
Demographic Percentage
Age (years) 52.3 (mean)
43.7 (25%ile) 60.6 (75%ile)
Gender 43.4% male/56.6% female
Ethnicity
Caucasian 81.5%
African-American 17.8%
Other 0.7%
Education
Less than high school (HS) 19.7%
HS 29.5%
Post HS 30.1%
College graduate 20.8%
General health
Smoker 22.2%
BMI 34.5 (mean)
SF12 (PCS) 40.6 (U.S. mean 50.0)
SF12 (MCS) 39.6 (U.S. mean 50.0)
n 5 379.
RESULTS
A total of 379 patients, representing 114 dif-
ferent physicians, were enrolled in the pro-
gram. Demographics, general health status,
and diabetic status are shown in Tables 1 and
2. The patient population was predominantly
middle aged, lower to middle socioeconomic
status, overweight, and below U.S. means in
health status as measured by the SF-12.
The study outcomes are shown in Tables 3–5
and Figure 1. Table 3 and Figure 1 show the
change in HbA1c for those patients for whom
both baseline and 6-month data were available.
The larger population shown in Table 2 had a
similar distribution of baseline values, but only
70 (18% of enrollment) had 6-month data, as
shown in Table 3. Overall, these patients
showed a mean decline in HbA1c of 1.7%, with
25% of patients showing a decline of 3% or
more. This improvement in HbA1c is statisti-
cally significant (p , 0.0001).
Clinical process measures of preventive dia-
betes care (Table 4) showed minor improve-
ment in rates between the 6-month pre- and
postenrollment periods; however, because
some preventive measures (e.g., eye exams) re-
quire only annual assessment, results must be
interpreted carefully.
Health-related quality of life was measured
using the SF-12, administered at enrollment
and at 6 months. Baseline and endpoint data
were available for 37 patients (10% of the en-
rolled population). For these patients, the phys-
ical component score declined slightly (39.5
versus 40.5, p 5 0.20), while the mental com-
ponent improved moderately (39.4 versus 36.5,
p 5 0.04).
Patient satisfaction was measured on a five-
point Likert scale. Survey questions assessed
patients’ satisfaction with their current diabetes
care at enrollment and at 6 months. Table 5
shows significant increase in satisfaction
among the 115 patients (38% of enrollment)
surveyed. In particular, patients’ satisfaction
with their knowledge of diabetes (p , 0.001),
their overall ability to take care of their diabetes
(p , 0.01), and how helpful they thought the
information was that they had received for tak-
ing care of their diabetes (p , 0.001) all showed
significant improvements.
Provider satisfaction was assessed at the end
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TABLE 2. DEMOGRAPHICS: DIABETES AT ENROLLMENT
Diabetes status (n 5 379)
Time since diagnosis Median ,1 year, 75%ile 5 5 years
Type I 8.8%
Type II 91.2%
HbA1c at enrollment 8.7 (mean)
(n 5 193)
Stratified groups (n 5 193)
In control ,7.0 21.8%
Borderline 7.0–8.0 21.7%
Moderate 8.1–10.0 28.0%
Severe .10.0 28.5%
TABLE 3. CLINICAL OUTCOME: CHANGE IN HBA1C
Stratified groups At baseline At 6 months
In control ,7.0 18.6% 54.3%
Borderline 7.0–8.0 24.3% 28.6%
Moderate 8.1–10.0 35.7% 15.7%
Severe .10.0 21.4% 1.4%
n 5 70.
61% improved at least one class; 29% stayed in the same
class; 10% moved to a worse class.
of the study through an anonymous question-
naire. Unfortunately, the response rate was
only 6%, and because of anonymity, it could
not be determined what percent of patients
were represented by these responders. There-
fore, the physician responses are not presented
in detail here, although all responses received
were strongly positive.
Surveys were administered at enrollment to
all 379 patients, and follow-up at 6 months was
done by mail, with a 30% response rate. Thus,
changes in patient satisfaction could be as-
sessed in a larger proportion of patients than
the 18% with complete clinical data. The pa-
tients were dispersed among over 100
providers, which made chart review and inter-
pretation a lengthy process, requiring an aver-
age of approximately 1 hour per chart. Charts
in different practices varied widely in com-
pleteness, especially with respect to dates of
service provided and legibility. The paper-
based chart system also lacks a uniform data
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TABLE 4. CLINICAL PROCESS MEASURES OF
COMPREHENSIVE DIABETES CARE
Percentage of patients with annual test/exam
6-month preenroll 6-month postenroll
Retinal exam 21.1 26.3
Foot exam 44.5 48.2
HbA1c 63.4 63.7
Lipid profile 50.5 45.3
Creatinine 46.3 42.6
Albumin 25.0 21.6
Glucose 67.6 68.7
Urinalysis 39.2 31.1
n 5 379.
TABLE 5. PATIENT SATISFACTION
Baseline 6 months
1. In the last 3 months, how satisfied have you been with your % “very satisfied” 32.3 63.5
1. knowledge of your diabetes?
2. In the last 3 months, how satisfied have you been with your % “very satisfied” 35.6 59.4
1. overall ability to take care of your diabetes?
3. In the last 3 months, how often have you been able to control % “frequently” 48.6 62.9
your blood sugar levels?
4. In the last 3 months, how often have your blood sugar levels % “frequently” 34.8 14.5
been high?
5. How satisfied are you with the medications that you take for % “very satisfied” 46.7 47.6
your diabetes?
6. How satisfied are you with the amount of information given to % “very satisfied” 42.7 54.5
you by your health plan about taking care of your diabetes?
7. How helpful is the amount of information given to you by your % “very helpful” 43.4 54.9
health plan about taking care of your diabetes?
8. Overall, how satisfied are you with your health plan’s diabetes % “very satisfied” 41.5 54.7
program?
9. How satisfied are you with the way the staff in the diabetes % “very satisfied” 57.9 68.2
program treat you?
10. How satisfied are you with the number of times that the % “very satisfied” 55.3 54.4
diabetes program staff have talked to you?
11. How likely are you to recommend your health plan’s diabetes % “very likely” 61.3 64.5
program to someone else who has your kind of diabetes?
n 5 115.
format. Because the patient appointment
schedule was not coordinated with enrollment,
judgment was required in interpreting the tim-
ing of the various events in the chart in rela-
tion to the pre- versus poststudy design.
DISCUSSION
Pilot study
The most notable positive outcomes of the
pilot evaluation are the measured decrease in
HbA1c and the high level of patient satisfac-
tion postenrollment in the Steps to Health™
program. The evaluable patient population ex-
perienced a 1.7% reduction in their HbA1c
level. The high level of patient satisfaction is
another indicator of success regarding the pro-
gram’s ability to increase patient knowledge
and understanding of their diabetes. It is diffi-
cult to directly compare the effectiveness of dif-
ferent diabetes disease management (DDM)
programs because outcomes are influenced by
differences in the respective populations: pro-
portion of type I/type II patients, age, years
since diagnosis, health status, lifestyle, and so-
cioeconomic and educational status. Neverthe-
less, published outcomes studies give an indi-
cation of the range of results that have been
achieved. While not a disease management
program, the Diabetes Control and Complica-
tions Trial (DCCT) provides a useful reference
point for type I glycemic control, achieving a
mean reduction in HbA1c of approximately
1.9% at 6 months in an intensively managed
population.4 Testa and Simonson.5 report on
results from a randomized, double-blind study
of glipizide versus placebo in a type 2 popula-
tion with similar demographics to the current
study. HbA1c declined 1% over the 15-week
study. Aubert et al.6 report on effectiveness of
nurse case management in a clinically similar
population in a group model HMO. O’Connor
et al.,7 McColloch et al.,8 and Sperl-Hillen et al.9
report on population-based approaches to dis-
ease management in the primary care setting.
Table 6 summarizes the results of these studies
with respect to glycemic control.
It is generally accepted that consistent pa-
tient self-management is the essential core of
diabetes care. Without patient commitment to
actively control glycemic levels and necessary
lifestyle changes, physicians must focus on pre-
vention and monitoring for complications so as
to diagnose them as soon as possible. Thus, the
Steps to Health™ program addresses the most
essential element of diabetes care. In a follow-
up survey, 68% of the patients who were using
the Steps to Health™ Diabetes Planner at the
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TABLE 6. ACHIEVEMENT OF GLYCEMIC CONTROL IN CONTROLLED STUDIES
Mean HbA1c (%)
Study Duration N1 Baseline End D
DCCT, 1983–93, clinical trial (intensive management IDDM) 6.5 years 348 8.8 6.92 1.92
Testa et al., 1998, clinical trial (glipizide in type 2 DM) 15 weeks 377 8.5 7.5 1.0
Aubert et al., 1998, nurse case management (Type 2) 12 months 71 9.0 7.3 1.7
O’Connor et al., 1996, CQI at HMO primary care clinics 12 months 122 8.9 8.4 0.5
McCulloch et al., 1998, population-based management in HMO 4 years 15,000 n/a3 7.6 n/a
Sperl-Hillen et al., 1999, DDM in large health system 12 months 5,940 7.86 7.47 0.39
1Includes treatment arm only.
2Estimated.
3Baseline not available.
FIG. 1. Glycemic control: pre- versus post-enrollment.
n 5 70.
end of the study were still using it 6 months
later.
This program targeted physician behavior
indirectly by offering physicians educational
monographs and attempting to increase patient
awareness of their diabetes care. As a result,
the intervention had a low impact on physician
behavior regarding the performance of ADA-
recommended routine diabetic tests/evalua-
tions and providing patient education in vari-
ous aspects of self-care. Although the changes
were low, the overall rates were in line with
nationwide data collected by the National
Committee for Quality Assurance (NCQA).
The Steps to Health™ program is designed to
maximize the benefits of patient self-manage-
ment by focusing on patient education and
compliance. For the long term, the program re-
lies on the Steps to Health™ Diabetes Planner,
the glucose meter provided, and quarterly re-
minder cards. Thus, excluding the costs of pro-
gram evaluation, the program is less resource
intensive than DDM programs that have on-
going patient meetings and events, diabetes ed-
ucators available on an ongoing basis, and for-
mal provider education. The relative cost of the
program is correspondingly low if the effec-
tiveness is measured, for example, by cost per
1-point reduction in HbA1c.
Implications
According to Zitter,10 the evolution of disease
management programs will follow four stages:
(1) programs that focus only on specific care el-
ements in individual patients; (2) programs that
target entire populations for high-impact inter-
ventions; (3) integrated care for entire popula-
tions; and (4) proactive health management of
entire populations. However, experience has
shown that these stages, rather than reflecting
the inevitable direction of evolution, may sim-
ply represent points on a cost continuum. The
program documented here contains elements
from type 1, i.e., primary focus on glycemic con-
trol, and type 2, in attempting to manage an en-
tire enrolled population rather than only identi-
fying high-utilization individuals within that
population. To the degree that it was able to ac-
complish these objectives at a relatively modest
cost per patient, the program demonstrates that
it is a viable alternative on the cost/benefit con-
tinuum.
Outcomes measurement
The experience gained in this program also
contains significant implications for the design
and administration of a disease management
program, specifically with respect to outcomes
measurement, outcomes reporting, and data
collection.
There are three clear implications for out-
comes measurement. First, there must be a
specified frequency of evaluation (e.g., every 6
months in the DDM program considered here),
and every patient must be assessed in every
time period. Although this may require signif-
icant additional effort and cost, program effec-
tiveness cannot be measured without reason-
ably complete data for all enrolled patients.
Second, the outcomes measured are deter-
mined by the program goals. According to the
ECHO model of outcomes measurement,11
these can be categorized as clinical, humanis-
tic, and economic. Clinical outcomes can be ei-
ther short term (e.g., improvement in glycemic
control) or long term (e.g., reduction of diabetic
complications). Process outcomes (e.g., perfor-
mance of specified tests at specified intervals)
may be used as measures of preventive care.
Humanistic outcomes include patient quality
of life (QOL) and satisfaction with care. Patient
satisfaction is especially important in a disease
such as diabetes where active, continuous pa-
tient self-care is essential to achieving good
clinical outcomes. Finally, economic outcomes
may be difficult to measure. Measurement of
cost savings requires both the cost of the pro-
gram and the costs avoided that can be attrib-
uted to the program. Because of the difficulty
in measuring the latter, cost-effectiveness out-
comes (e.g., cost per emergency department
visit avoided) are often the most feasible eco-
nomic outcomes to measure.
Outcomes reporting
Outcomes reporting, on the surface a rela-
tively simple process, involves several signifi-
cant conceptual issues. The most obvious issue
is that any numerical measures at the patient
level require a defined population (i.e., a de-
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nominator). Given steady enrollment of new
patients and some rate of drop out, there must
be an estimate of the effective patient popula-
tion during a given time period. A more dif-
ficult issue is the attribution of outcomes. If
the program is closely integrated with a pri-
mary care network, it would be virtually im-
possible to differentiate the effects of physi-
cian care from the incremental clinical benefits
attributable to the program. A third issue is
risk or severity adjustment of the patient pop-
ulation. In the analysis reported here, stratifi-
cation of the population by level of glycemic
control at enrollment was necessary in order
to interpret the outcomes. For valid compari-
son to external benchmarks, differences in pa-
tient populations must be taken into account.
Finally, it is important to distinguish between
ongoing management reporting and one-time
research evaluations of the kind described in
this study.
Management reporting requires identifica-
tion of needed data elements and their sources
(e.g., charts, claims, questionnaires), and sys-
tems to collect and process the data. Data ele-
ments required for ongoing program monitor-
ing and reporting include the following:
demographic, clinical, health services utiliza-
tion, education received, process checkoffs, pa-
tient satisfaction, and disease-specific clinical
markers. It is essential that, for all event data
collected, dates are included.
CONCLUSION
Disease management is an information-in-
tensive process, requiring information systems
capability that goes well beyond the require-
ments of the individual patient chart. The level
of investment required can be daunting, espe-
cially in a setting where the patient charts
themselves, the primary source of clinical data
elements, are not electronically accessible. The
process of manual chart review used in the cur-
rent study, while feasible for a one-time evalu-
ation, is much too labor intensive for ongoing
data collection. In addition, the chart review re-
vealed great variability in data quality across
the individual practices of over 100 primary
care physicians. For process measures of clini-
cal care, seemingly the easiest outcomes to doc-
ument, the question when reviewing charts
was whether a test or exam was not done, or
done and not documented. Health services uti-
lization (claims data), while not collected in the
current pilot study, would be a valuable com-
ponent of a full-featured disease management
program. Disease management also requires
ongoing collection of self-reported patient data
(QOL, satisfaction). The question then becomes
whether the requirements of disease manage-
ment are best served by dedicated information
systems running in parallel to existing clinical
and administrative systems, or by management
reporting software fed by data extracts from ex-
isting databases. It is likely that health care sup-
pliers will develop products along both lines
with the state of existing infrastructure and the
funds budgeted determining the choice of dis-
ease management system.
The data presented here suggest that a rela-
tively inexpensive and easy-to-implement dia-
betes disease management program, centered
on patient education in self-management, can
achieve clinically significant improvements in
glycemic control for a specific period of time (6
months), and result in a high level of patient
satisfaction. In addition to issues of data man-
agement, this study illustrates that the degree
of physician integration is one of the most
salient features of a disease management pro-
gram. A centralized program that is more in-
tegrated with individual physician practices
and focused on provider education would pre-
sumably produce even better results, but at a
significantly higher cost. Measuring the cost ef-
fectiveness of disease management programs is
one of the most pressing areas for further re-
search. Studies of the long-term effects of dia-
betes disease management programs are par-
ticularly needed in order to demonstrate both
short- and long-term value to health care
providers and organizations.
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